Autopsy report · NCT04563195

BAFF/IL-17 Bispecific Antibody Treatment in Subjects With Primary Sjogren's Syndrome

“Drug unavailable”

The sponsor’s own words in the registry.

Life of this trial

• Withdrawn before it enrolled anyone. Its dates are the sponsor's plans, not events that happened.

Vital statistics

Status

Withdrawn

Phase

Phase 2, Phase 3

Sponsor

Matthew C. Baker

Sponsor type

University, hospital or other

Conditions

Primary Sjogren's Syndrome

Interventions

tibulizumab (LY3090106)

Participants

0

Sites

1

Countries

United States

Trials that died the same way

• Role of Oxytocin in Telling and Detecting Lies
  “Drug not available” (93% match in meaning)
• Phase I Study of CS-7017 and Bexarotene
  “Drug no longer available” (87% match in meaning)
• Bicalutamide and RO4929097 in Treating Patients With Previously Treated Prostate Cancer
  “Drug was no longer available” (83% match in meaning)
• Letrozole and Celecoxib in Treating Postmenopausal Women With Locally Advanced or Metastatic Breast Cancer
  “study drug unavailable” (81% match in meaning)
• Biased Opioid Agonists for Treatment of Opioid Withdrawal in OUD
  “Drug availability” (81% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.